Evidence map›Paper›PMID 42422860›Full record

ArticleInflammatory intestinal diseases

Real-World Efficacy of Ustekinumab versus Vedolizumab for Ulcerative Colitis: Differences between Short- and Long-Term Outcomes Based on Endoscopic Remission.

Makoto Furuya, Jun Kato, Ken Takeuchi, Kento Shimizu, Toshiyuki Ito, Nobuaki Shu, Yusuke Ozeki, Ryosuke Horio, Chihiro Goto, Tsubasa Ishikawa and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammatory intestinal diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Makoto FuruyaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Jun KatoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Ken TakeuchiDepartment of Gastroenterology, IBD Center, Tsujinaka Hospital Kashiwanoha, Chiba, Japan.
Kento ShimizuDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Toshiyuki ItoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Nobuaki ShuDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yusuke OzekiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Ryosuke HorioDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Chihiro GotoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tsubasa IshikawaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hirotaka OuraDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tatsuya KanekoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yuki OhtaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takashi TaidaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kenichiro OkimotoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Keiko SaitoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tomoaki MatsumuraDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Ustekinumab (UST) and vedolizumab (VED) are effective for ulcerative colitis (UC), but long-term real-world data, particularly regarding endoscopic remission, remain limited. Methods: Patients with UC who were treated with UST or VED at two tertiary centers were enrolled in this retrospective study. Baseline imbalances were adjusted using inverse probability of treatment weighting. The primary outcome was the endoscopic remission rates (Mayo Endoscopic Subscore [MES] 0 or 1 and MES 0 alone) at 1 year and 2 years. Secondary outcomes included clinical remission rates and treatment persistence. Results: Overall, 197 patients were analyzed: 96 received UST, and 101 received VED. The median observation period was 2.5 years. Clinical remission rates did not differ between the two groups. Treatment persistence was higher with UST than with VED (HR: 1.85; 95% CI: 1.13-3.02; Conclusion: UST was associated with a higher rate of achieving MES 0 or 1, while deep remission rates were comparable. This may explain a more pronounced difference in treatment persistence in the short-term phase, with the difference decreasing over time.

Indexed as

Endoscopic remissionTreatment persistenceUlcerative colitisUstekinumabVedolizumab

Identifiers

PMID42422860
PMCPMC13345622

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.